Role of Gut Microbiome in Cancer Therapy

Status Recruiting

Clinical Trial Summary

This study examines how gut microbiome can affect cancer therapy in cancer patients undergoing cancer therapy or stem cell transplant. The human microbiome affects the way some cancer drugs are metabolized in the human body. Information from this study may help doctors improve the way cancer treatment is delivered, and increase its effectiveness and success.

Clinical Trial Description

PRIMARY OBJECTIVE: I. To correlate gut microbiome with specific cancer diagnoses and the clinical response (efficacy), and adverse effects of cancer therapy (single or multiple) and stem cell transplant. OUTLINE: Patients undergo collection of blood and stool samples and have their medical records reviewed. ;

Study Design

Related Conditions & MeSH terms

Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Neoplasms

Clinical Trial Details

NCT number	NCT05112614
Study type	Observational
Source	Mayo Clinic
Contact
Status	Recruiting
Phase
Start date	September 11, 2019
Completion date	October 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06030427` - Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors	N/A
Completed	`NCT04337203` - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship	N/A
Recruiting	`NCT05660421` - Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors	Phase 2
Suspended	`NCT04060849` - Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY	Phase 1
Recruiting	`NCT06192875` - A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)
Completed	`NCT04122118` - Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor	N/A
Active, not recruiting	`NCT04940299` - Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma	Phase 2
Active, not recruiting	`NCT03168737` - 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients	Phase 1
Active, not recruiting	`NCT06062901` - An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors	N/A
Active, not recruiting	`NCT02444741` - Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer	Phase 1/Phase 2
Terminated	`NCT04081298` - eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors	N/A
Active, not recruiting	`NCT04555837` - Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer	Phase 1/Phase 2
Completed	`NCT04983901` - PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN	Phase 2
Active, not recruiting	`NCT04602026` - The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer	N/A
Recruiting	`NCT04871542` - Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Active, not recruiting	`NCT04592250` - Financial Toxicity in Cancer Patients
Active, not recruiting	`NCT04296305` - Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain	Phase 4
Recruiting	`NCT05873608` - Communication Issues in Patient and Provider Discussions of Immunotherapy	N/A
Recruiting	`NCT02464696` - Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure	N/A
Recruiting	`NCT05372614` - Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene	Phase 1